Overview
Mogrify is a regenerative medicine company developing a novel class of in vivo cellular reprogramming therapies targeting degenerative diseases with high unmet clinical need. The company leverages proprietary computational platforms to identify optimal combinations of transcription factors and growth factors required to convert one cell type into another, enabling direct cellular transdifferentiation. Mogrify's therapeutic pipeline addresses sensorineural hearing loss, retinal degeneration, and Type I diabetes through both ex vivo and in vivo reprogramming approaches. The company combines systematic big-data analysis with next-generation sequencing and epigenetic network data to accelerate the development of functional cell types for regenerative medicine applications.